NVL-655 is a novel, brain-penetrant, ALK-selective tyrosine kinase inhibitor (TKI) developed to address emergent treatment resistance and brain metastases while minimizing off-target central nervous ...

NVL-655 is under clinical development by Nuvalent and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase ...

Nuvalent, Inc., a clinical-stage biopharmaceutical company, announced the initiation of the phase 2 portion of ALKOVE-1, its phase 1/2 clinical trial of NVL-655 for patients with ALK-positive ...

CAMBRIDGE, Mass. - Nuvalent, Inc. (NASDAQ : NUVL), a clinical-stage biopharmaceutical company, announced today the initiation of the Phase 2 portion of its ALKOVE-1 clinical trial, which will test NVL ...

The revenue for NVL-655 is expected to reach an annual total of $129 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...

CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

As determined by phase 1 of the ARROS-1 study, patients with ROS1-positive non–small cell lung cancer and other solid tumors will be further assessed with the recommended phase 2 dose of NVL-520 in ...

The first pretreated patient with HER2-altered non–small cell lung cancer was dosed with NVL-330, a novel HER2-selective inhibitor, in the HEROEX-1 trial. The phase 1a/1b HEROEX-1 trial has begun and ...

Preclinical characterization of NVL-330, a selective and brain penetrant HER2 tyrosine kinase inhibitor with broad activity on HER2 oncogenic alterations Authors: Yuting Sun 1, Kristin L. Andrews 1, ...

Purpose Antinuclear valosin-containing protein-like protein (NVL) antibodies have been detected only in systemic sclerosis (SSc) patients, and diverse comorbidities have been reported in anti-NVL ...